Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom

Clalit Health Services

Status and phase: Unknown; Phase 4

Conditions: Hypertension; Glaucoma

Treatments: Device: Xal-Ease

Study type: Interventional

Funder types: Other

Identifiers

NCT01125306

GLAUCOMA/XAL EASE 1

Details and patient eligibility

About

Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation.

Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed more than one bottle per month within a year prior to initiation of the study.

Exclusion criteria

• Patients younger than 18 years,
• Patients with severe manual disabilities,
• Patients with impaired cognition and mentality.

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

Sponsor of this trial

Lead Sponsor

Clalit Health Services